Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-701 for EGFR Inhibitor-Induced Skin Rash
NCT04239846Phase 2Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acneiform eruption comparing AC-701 with Placebo (2 arms). Primary endpoint: Number of subjects with MESTT Grade 0 or 1 at 4 weeks. Started Oct 2019; status: completed.
02
Drugs
AC-701
03
Conditions
acneiform eruption
Beyond the preview
Go deeper on NCT04239846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239846.